Blythe Adamson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Blythe Adamson has a total of 237 co-authors. Here are the top co-authors by number of shared publications:
- Dobromir Dimitrov
Fred Hutchinson Cancer Center
4 shared publications - Melissa Estevez
Flatiron Health, New York, NY
4 shared publications - Aaron B. Cohen
Flatiron Health, New York, NY
3 shared publications Dobromir Dimitrov
Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA
3 shared publications- James G. Kublin
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA
3 shared publications - Louis P. Garrison
Affiliations The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, Washington, United States of America, VeriTech Corporation, Mercer Island, Washington, United States of America
3 shared publications
Latest Publications
- 1 November 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (11)
On the economics of broadly neutralizing monoclonal antibodies for HIV prevention in high-income countries
Aim: To quantify the market opportunity and economic impact of broadly neutralizing monoclonal antibodies (bnAbs) as a novel HIV prevention modality in high-income countries. Materials & methods: Using a decision-tree and revenue model applied to an eligible US population of 1299,708 individuals and projecting to 2040, bnAbs are estimated to capture 1 in 8 PrEP users (12.5% of PrEP users, 95% credible interval 7.3% to 21.1%, equivalent to 8.0% of the prevention-eligible population) following assumed US FDA approval in 2030. All estimates are scenario based and conditional on assumed pricing, uptake and behavior; none are observed outcomes. Critically, roughly half of projected bnAb users, nearly 52,000 individuals, would not otherwise use any biomedical HIV prevention, representing a net expansion of PrEP users (95% credible interval: 21,859–95,581). US manufacturer revenue totaled $12.0 billion discounted at 3% per year to 2030 (95% credible interval $6.2 billion to $21.9 billion), equivalent to $14.5 billion undiscounted, over the 11 years from approval to 2040. Total US payer spending rose 3.6% ($463.6 million annually), though the credible interval crosses zero, and the mean cost per prevention user decreased provided bnAbs are priced at the modeled list price of $14,000 per year, below existing injectable PrEP options. Conclusion: Under the assumptions modeled here, bnAbs could reach roughly one in eight PrEP users in high-income countries, about half of them people not otherwise using biomedical prevention. Whether this translates into an attractive commercial opportunity, and whether per-user prevention costs fall or rise, depends principally on how bnAbs are priced relative to long-acting injectable PrEP. These are projections conditional on assumed efficacy, pricing and adoption behavior, not observed outcomes.
- 1 November 2026
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 15 (11)
On the economics of broadly neutralizing monoclonal antibodies for HIV prevention in high-income countries
Aim: To quantify the market opportunity and economic impact of broadly neutralizing monoclonal antibodies (bnAbs) as a novel HIV prevention modality in high-income countries. Materials & methods: Using a decision-tree and revenue model applied to an eligible US population of 1299,708 individuals and projecting to 2040, bnAbs are estimated to capture 1 in 8 PrEP users (12.5% of PrEP users, 95% credible interval 7.3% to 21.1%, equivalent to 8.0% of the prevention-eligible population) following assumed US FDA approval in 2030. All estimates are scenario based and conditional on assumed pricing, uptake and behavior; none are observed outcomes. Critically, roughly half of projected bnAb users, nearly 52,000 individuals, would not otherwise use any biomedical HIV prevention, representing a net expansion of PrEP users (95% credible interval: 21,859–95,581). US manufacturer revenue totaled $12.0 billion discounted at 3% per year to 2030 (95% credible interval $6.2 billion to $21.9 billion), equivalent to $14.5 billion undiscounted, over the 11 years from approval to 2040. Total US payer spending rose 3.6% ($463.6 million annually), though the credible interval crosses zero, and the mean cost per prevention user decreased provided bnAbs are priced at the modeled list price of $14,000 per year, below existing injectable PrEP options. Conclusion: Under the assumptions modeled here, bnAbs could reach roughly one in eight PrEP users in high-income countries, about half of them people not otherwise using biomedical prevention. Whether this translates into an attractive commercial opportunity, and whether per-user prevention costs fall or rise, depends principally on how bnAbs are priced relative to long-acting injectable PrEP. These are projections conditional on assumed efficacy, pricing and adoption behavior, not observed outcomes.
- Open Access
- 17 September 2026
- Published by Elsevier in SSRN Electronic Journal
Pro-Worker AI in Health: Who Benefits When Machines Enter the Largest Workforce in America?
The US health sector accounts for 18.0% of gross domestic product and roughly one in eight jobs, yet the labor market consequences of the artificial intelligence (AI) products now being deployed across it have not been systematically inventoried. This paper applies the Acemoglu, Autor, and Johnson (2026) five-category pro-worker framework to a structured environmental scan of 132 commercially deployed or FDA-authorized AI-enabled health technologies identified in March 2026 across five domains: clinical care, provider administration, payer administration, life sciences, and public health. Each technology was classified under a pre-specified protocol by the anticipated direction of its effect on labor productivity, the value of human expertise, and labor's share of income. Within this scan, 41.7% of technologies were classified as automating existing tasks, 29.5% as creating new tasks, 16.7% as expertise-leveling, 10.6% as labor-augmenting, and 1.5% as capital-augmenting. The classifications diverge sharply by domain. Of 40 provider- and payer-administration technologies, 39 (97.5%) were classified as automation. Of 92 technologies in clinical care, life sciences, and public health, 61 (66.3%) were classified as new task-creating or expertise-leveling. These are classifications of anticipated consequences, not measurements of employment, wages, or income shares. I offer an economic interpretation of the pattern as a set of testable hypotheses: administrative tasks are rule-bound and algorithmically reducible, whereas clinical and scientific judgment sustains demand for human expertise, and the distribution of any productivity gains depends on payment incentives, provider and employer market power, and workforce regulation. I describe a friction-cost paradox, in which the workers most exposed to automation perform work that exists largely because of insurance and billing complexity, and I propose five policy levers with responsible actors and evaluation criteria. The scan is limited to commercially oriented products and cannot support conclusions about net employment effects or about the level of investment in public health AI.
- 17 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPro-Worker AI in Health: Who Benefits When Machines Enter the Largest Workforce in America?
The US health sector accounts for 18.0% of gross domestic product and roughly one in eight jobs, yet the labor market consequences of the artificial intelligence (AI) products now being deployed across it have not been systematically inventoried. This paper applies the Acemoglu, Autor, and Johnson (2026) five-category pro-worker framework to a structured environmental scan of 132 commercially deployed or FDA-authorized AI-enabled health technologies identified in March 2026 across five domains: clinical care, provider administration, payer administration, life sciences, and public health. Each technology was classified under a pre-specified protocol by the anticipated direction of its effect on labor productivity, the value of human expertise, and labor's share of income. Within this scan, 41.7% of technologies were classified as automating existing tasks, 29.5% as creating new tasks, 16.7% as expertise-leveling, 10.6% as labor-augmenting, and 1.5% as capital-augmenting. The classifications diverge sharply by domain. Of 40 provider- and payer-administration technologies, 39 (97.5%) were classified as automation. Of 92 technologies in clinical care, life sciences, and public health, 61 (66.3%) were classified as new task-creating or expertise-leveling. These are classifications of anticipated consequences, not measurements of employment, wages, or income shares. I offer an economic interpretation of the pattern as a set of testable hypotheses: administrative tasks are rule-bound and algorithmically reducible, whereas clinical and scientific judgment sustains demand for human expertise, and the distribution of any productivity gains depends on payment incentives, provider and employer market power, and workforce regulation. I describe a friction-cost paradox, in which the workers most exposed to automation perform work that exists largely because of insurance and billing complexity, and I propose five policy levers with responsible actors and evaluation criteria. The scan is limited to commercially oriented products and cannot support conclusions about net employment effects or about the level of investment in public health AI.
- Open Access
- 30 June 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 13, 100727
A scoping review of real-world data sources for retrospective oncology analysis in Japan
- 30 June 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 13, 100727
Open AccessA scoping review of real-world data sources for retrospective oncology analysis in Japan
- Open Access
- 3 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (15) , 5325-5337
Real-World Treatment Patterns of Patients with Large B-cell Lymphoma Over Time and into a Post-CAR T Approval Era
A significant proportion of patients with large B-cell lymphoma (LBCL) experience relapsed or refractory (R/R) disease after first-line therapy. Chimeric antigen receptor T-cell (CAR T) therapy is approved for R/R LBCL, yet real-world utilization remains unclear. This retrospective study evaluated treatment patterns and survival outcomes in patients potentially eligible for CAR T in the Flatiron Health Research Database. Patients diagnosed with LBCL from 2011-2024 who initiated a first-line therapy were assessed. Predictors of mortality before the opportunity to initiate second-line therapy were evaluated using competing risk regression models. Treatment patterns among a subgroup that initiated second-line and third-line therapy based on the dates of FDA indication approvals for CAR T were evaluated and stratified by fitness for CAR T based on age and ECOG score. Among 10,016 patients that initiated first-line therapy, 13% died within 1 year without initiating second-line, and 30% initiated second-line. In competing risk analyses, 11% of patients with ECOG score of 0/1/unknown (combined) died within 12 months of initiating first-line therapy, and before being able to receive a second-line therapy. Among patients deemed eligible and fit for CAR T, 25% received second-line CAR T, and 36% received third-line CAR T. Despite its curative potential, CAR T uptake remains low in potentially eligible patients, with many dying within 1 year of initiating first-line therapy and before the opportunity to receive CAR T. Early collaboration between the community oncologist and CAR T center, improved access, and expanded patient awareness strategies are needed to improve CAR T therapy uptake.
- 3 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (15) , 5325-5337
Open AccessReal-World Treatment Patterns of Patients with Large B-cell Lymphoma Over Time and into a Post-CAR T Approval Era
A significant proportion of patients with large B-cell lymphoma (LBCL) experience relapsed or refractory (R/R) disease after first-line therapy. Chimeric antigen receptor T-cell (CAR T) therapy is approved for R/R LBCL, yet real-world utilization remains unclear. This retrospective study evaluated treatment patterns and survival outcomes in patients potentially eligible for CAR T in the Flatiron Health Research Database. Patients diagnosed with LBCL from 2011-2024 who initiated a first-line therapy were assessed. Predictors of mortality before the opportunity to initiate second-line therapy were evaluated using competing risk regression models. Treatment patterns among a subgroup that initiated second-line and third-line therapy based on the dates of FDA indication approvals for CAR T were evaluated and stratified by fitness for CAR T based on age and ECOG score. Among 10,016 patients that initiated first-line therapy, 13% died within 1 year without initiating second-line, and 30% initiated second-line. In competing risk analyses, 11% of patients with ECOG score of 0/1/unknown (combined) died within 12 months of initiating first-line therapy, and before being able to receive a second-line therapy. Among patients deemed eligible and fit for CAR T, 25% received second-line CAR T, and 36% received third-line CAR T. Despite its curative potential, CAR T uptake remains low in potentially eligible patients, with many dying within 1 year of initiating first-line therapy and before the opportunity to receive CAR T. Early collaboration between the community oncologist and CAR T center, improved access, and expanded patient awareness strategies are needed to improve CAR T therapy uptake.
- Open Access
- 17 May 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (6) , e70396
Transportability Analyses in Comparative Effectiveness Research: A Conceptual Framework and Methodological Principles Endorsed by the I nternational S ociety for P harmacoepidemiology
The Problem: Transportability considerations are increasingly important to answer research questions in comparative effectiveness research (CER) to support the transfer of evidence on medicinal products across countries or settings. As drug development costs rise and healthcare systems and professionals face economic and resource pressures, leveraging existing data and evidence generated across borders or settings can improve efficiency and inform decisions in product development and decision‐making (regulatory, health technology assessment [HTA] and clinical care). Differences in population characteristics, healthcare systems, and data availability, including coding discrepancies, may present significant challenges to the transportability of CER evidence. Without rigorous methodological approaches, the utility of transportability analyses is limited. What we Did: This article provides a structured framework for considering transportability exercises in CER analyses. We outlined key methodological principles, when and why to use transportability exercises in CER, feasibility assessments including effect modifier identification and causal inference techniques such as weighting, outcome regression, and combined methods to guide transportability analytical approaches in CER. By synthesizing existing literature and expert insights, we identified opportunities and trade‐offs in applying transportability methods to support decisions across the product lifecycle. Strategies to Disseminate and Facilitate Use: To enhance the adoption of transportability analyses, we proposed best practices for researchers, regulators, HTA bodies, and industry stakeholders. These include early engagement with regulatory agencies and HTA bodies, transparent documentation of data assumptions, quality, fitness, and comparability assessments while ensuring robust analytical approaches. We also emphasized the need for standardized reporting guidelines and cross‐country collaborations to validate transportability methods in real‐world settings and communicate uncertainty in transported evidence. Conclusions: Transportability analyses offer a powerful tool for extending the applicability of CER findings across healthcare systems, improving evidence generation efficiency, and supporting global drug development and evaluation. By implementing best practices that promote a rigorous and transparent approach to the design and conduct of such analyses, stakeholders can maximize the value of transported treatment effects while ensuring scientific rigor and decision‐making relevance. Future research should focus on empirical testing and validation of transportability methods targeting different questions across the product lifecycle and the development of harmonized regulatory and HTA methodological standards. “This manuscript is endorsed by the International Society for Pharmacoepidemiology (ISPE).” Official Endorsement was received on 5/13/26.
- 17 May 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (6) , e70396
Open AccessTransportability Analyses in Comparative Effectiveness Research: A Conceptual Framework and Methodological Principles Endorsed by the I nternational S ociety for P harmacoepidemiology
The Problem: Transportability considerations are increasingly important to answer research questions in comparative effectiveness research (CER) to support the transfer of evidence on medicinal products across countries or settings. As drug development costs rise and healthcare systems and professionals face economic and resource pressures, leveraging existing data and evidence generated across borders or settings can improve efficiency and inform decisions in product development and decision‐making (regulatory, health technology assessment [HTA] and clinical care). Differences in population characteristics, healthcare systems, and data availability, including coding discrepancies, may present significant challenges to the transportability of CER evidence. Without rigorous methodological approaches, the utility of transportability analyses is limited. What we Did: This article provides a structured framework for considering transportability exercises in CER analyses. We outlined key methodological principles, when and why to use transportability exercises in CER, feasibility assessments including effect modifier identification and causal inference techniques such as weighting, outcome regression, and combined methods to guide transportability analytical approaches in CER. By synthesizing existing literature and expert insights, we identified opportunities and trade‐offs in applying transportability methods to support decisions across the product lifecycle. Strategies to Disseminate and Facilitate Use: To enhance the adoption of transportability analyses, we proposed best practices for researchers, regulators, HTA bodies, and industry stakeholders. These include early engagement with regulatory agencies and HTA bodies, transparent documentation of data assumptions, quality, fitness, and comparability assessments while ensuring robust analytical approaches. We also emphasized the need for standardized reporting guidelines and cross‐country collaborations to validate transportability methods in real‐world settings and communicate uncertainty in transported evidence. Conclusions: Transportability analyses offer a powerful tool for extending the applicability of CER findings across healthcare systems, improving evidence generation efficiency, and supporting global drug development and evaluation. By implementing best practices that promote a rigorous and transparent approach to the design and conduct of such analyses, stakeholders can maximize the value of transported treatment effects while ensuring scientific rigor and decision‐making relevance. Future research should focus on empirical testing and validation of transportability methods targeting different questions across the product lifecycle and the development of harmonized regulatory and HTA methodological standards. “This manuscript is endorsed by the International Society for Pharmacoepidemiology (ISPE).” Official Endorsement was received on 5/13/26.
- 26 April 2026
- Published by SAGE Publications in Medical Decision Making
- Vol. 46 (5) , 601-623
Using Regression Discontinuity in Time to Strengthen Real-World Evidence: A Case Study in Lung Cancer
Objective: Real-world evidence is increasingly leveraged to assess treatment effectiveness outside of clinical trials, yet unmeasured confounders and missing data pose challenges to causal inference, which is particularly problematic when incorporating historical controls that lack recent prognostic factors. We applied the regression discontinuity in time (RDiT) design, a quasi-experimental approach, in a real-world case study of second-line pembrolizumab versus docetaxel for advanced non-small-cell lung cancer (aNSCLC). We compared results from the RDiT method with time-stratified inverse probability treatment weighting (ts-IPTW), benchmarking results against long-term trial data. Methods: We conducted a retrospective cohort study of patients who received second-line pembrolizumab or docetaxel after platinum-based chemotherapy between 2011 and 2023. The introduction of pembrolizumab (Q2 2016) served as the discontinuity threshold in an RDiT framework, with treatment probabilities estimated via logistic regression. Survival outcomes, including hazard ratios (HRs), median overall survival, and restricted mean survival time (RMST), were compared across RDiT, ts-IPTW, and reconstructed trial estimates. Data Sources: This study used the US-based, electronic health record–derived deidentified Flatiron Health Research Database. Results: Among 1,975 patients (1,014 pembrolizumab, 961 docetaxel), RDiT estimated an adjusted median survival of 11.5 mo for pembrolizumab versus 6.9 mo for docetaxel (HR 0.65, 95% confidence interval [CI]: 0.48, 0.89), compared with ts-IPTW (HR 0.52, 95% CI: 0.42, 0.64) and 5-y trial data (HR 0.70, 95% CI: 0.61, 0.80). RDiT produced smaller survival gains that were better aligned with trial results relative to ts-IPTW, suggesting it may help mitigate unmeasured confounding in real-world studies. Conclusions: The RDiT may provide effect estimates more consistent with trial data, particularly when confounding is a concern. More research is required to examine its performance in other applications. Highlights: The regression discontinuity in time (RDiT) method incorporates historical controls and addresses unobserved confounders to strengthen causal inference. Compared with traditional propensity score–based approaches, RDiT accommodates historical and concurrent controls and reduces reliance on comprehensive measurement of observed confounders when treatment practices or biomarkers change over time. As real-world evidence increasingly informs regulatory, coverage, and pricing decisions, rigorous analytic methods are essential to produce credible and decision-relevant estimates.
- 26 April 2026
- Published by SAGE Publications in Medical Decision Making
- Vol. 46 (5) , 601-623
Using Regression Discontinuity in Time to Strengthen Real-World Evidence: A Case Study in Lung Cancer
Objective: Real-world evidence is increasingly leveraged to assess treatment effectiveness outside of clinical trials, yet unmeasured confounders and missing data pose challenges to causal inference, which is particularly problematic when incorporating historical controls that lack recent prognostic factors. We applied the regression discontinuity in time (RDiT) design, a quasi-experimental approach, in a real-world case study of second-line pembrolizumab versus docetaxel for advanced non-small-cell lung cancer (aNSCLC). We compared results from the RDiT method with time-stratified inverse probability treatment weighting (ts-IPTW), benchmarking results against long-term trial data. Methods: We conducted a retrospective cohort study of patients who received second-line pembrolizumab or docetaxel after platinum-based chemotherapy between 2011 and 2023. The introduction of pembrolizumab (Q2 2016) served as the discontinuity threshold in an RDiT framework, with treatment probabilities estimated via logistic regression. Survival outcomes, including hazard ratios (HRs), median overall survival, and restricted mean survival time (RMST), were compared across RDiT, ts-IPTW, and reconstructed trial estimates. Data Sources: This study used the US-based, electronic health record–derived deidentified Flatiron Health Research Database. Results: Among 1,975 patients (1,014 pembrolizumab, 961 docetaxel), RDiT estimated an adjusted median survival of 11.5 mo for pembrolizumab versus 6.9 mo for docetaxel (HR 0.65, 95% confidence interval [CI]: 0.48, 0.89), compared with ts-IPTW (HR 0.52, 95% CI: 0.42, 0.64) and 5-y trial data (HR 0.70, 95% CI: 0.61, 0.80). RDiT produced smaller survival gains that were better aligned with trial results relative to ts-IPTW, suggesting it may help mitigate unmeasured confounding in real-world studies. Conclusions: The RDiT may provide effect estimates more consistent with trial data, particularly when confounding is a concern. More research is required to examine its performance in other applications. Highlights: The regression discontinuity in time (RDiT) method incorporates historical controls and addresses unobserved confounders to strengthen causal inference. Compared with traditional propensity score–based approaches, RDiT accommodates historical and concurrent controls and reduces reliance on comprehensive measurement of observed confounders when treatment practices or biomarkers change over time. As real-world evidence increasingly informs regulatory, coverage, and pricing decisions, rigorous analytic methods are essential to produce credible and decision-relevant estimates.
- Open Access
- 10 January 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Real-world evidence from Germany: representativeness analysis and mortality endpoint validation in electronic health record-derived oncology cohorts
High-quality real-world data (RWD) for oncology research remains limited in Germany despite significant clinical need. Electronic health record (EHR)-deriv
- 10 January 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessReal-world evidence from Germany: representativeness analysis and mortality endpoint validation in electronic health record-derived oncology cohorts
High-quality real-world data (RWD) for oncology research remains limited in Germany despite significant clinical need. Electronic health record (EHR)-deriv
- Top Cited PapersOpen Access
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (1) , e2500215
Ensuring Reliability of Curated Electronic Health Record–Derived Data: The Validation of Accuracy for Large Language Model–/Machine Learning–Extracted Information and Data (VALID) Framework
Large language models (LLMs) are increasingly used to extract clinical data from electronic health records, offering significant improvements in scalability and efficiency for real-world data (RWD) curation in oncology. However, the adoption of LLMs introduces new challenges in ensuring the reliability, accuracy, and fairness of extracted data, which are essential for research, regulatory, and clinical applications. Existing quality assurance frameworks for RWD and artificial intelligence (AI) do not fully address the unique error modes and complexities associated with LLM-extracted data. In this paper, we propose a comprehensive framework for evaluating the quality of clinical data extracted by LLMs. The framework integrates variable-level performance benchmarking against expert human abstraction, verification checks for internal consistency and plausibility, and replication analyses comparing LLM-extracted data to human-abstracted data sets or external standards. This multidimensional approach enables the identification of variables most in need of improvement, systematic detection of latent errors, and confirmation of data set fitness-for-purpose in real-world research. Additionally, the framework supports bias assessment by stratifying across demographic subgroups. By providing a rigorous and transparent method for assessing LLM-extracted RWD, this framework advances industry standards and supports the trustworthy use of AI-powered evidence generation in oncology research and practice.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (1) , e2500215
Top Cited PapersOpen AccessEnsuring Reliability of Curated Electronic Health Record–Derived Data: The Validation of Accuracy for Large Language Model–/Machine Learning–Extracted Information and Data (VALID) Framework
Large language models (LLMs) are increasingly used to extract clinical data from electronic health records, offering significant improvements in scalability and efficiency for real-world data (RWD) curation in oncology. However, the adoption of LLMs introduces new challenges in ensuring the reliability, accuracy, and fairness of extracted data, which are essential for research, regulatory, and clinical applications. Existing quality assurance frameworks for RWD and artificial intelligence (AI) do not fully address the unique error modes and complexities associated with LLM-extracted data. In this paper, we propose a comprehensive framework for evaluating the quality of clinical data extracted by LLMs. The framework integrates variable-level performance benchmarking against expert human abstraction, verification checks for internal consistency and plausibility, and replication analyses comparing LLM-extracted data to human-abstracted data sets or external standards. This multidimensional approach enables the identification of variables most in need of improvement, systematic detection of latent errors, and confirmation of data set fitness-for-purpose in real-world research. Additionally, the framework supports bias assessment by stratifying across demographic subgroups. By providing a rigorous and transparent method for assessing LLM-extracted RWD, this framework advances industry standards and supports the trustworthy use of AI-powered evidence generation in oncology research and practice.
- Open Access
- 21 November 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 10
Transportability of overall survival estimates from the USA to France in patients with metastatic triple-negative breast cancer
- 21 November 2025
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 10
Open AccessTransportability of overall survival estimates from the USA to France in patients with metastatic triple-negative breast cancer
- Open Access
- 3 September 2025
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (1) , 8-18
Real-world data and evidence in pain research: an IMMPACT comprehensive review and best practice recommendations
Real-world data (RWD) can be defined as routinely collected clinical or administrative data that might be used for research purposes and to generate real-world evidence (RWE). Computerized search and data mining methods, large electronic databases, and the development of novel computational and statistical methods allow for improved access to and analysis of RWD. Although RWD afford the opportunity to generate RWE with potentially improved efficiency and generalizability over prospective clinical studies, it is important to understand and apply best practices when analysing RWD, particularly when the goal is to generate RWE of diagnostic, prognostic, or treatment effectiveness. Real-world evidence can provide evidence complementary to randomized clinical trials (RCTs), especially in scenarios where RCTs are difficult to conduct. Real-world evidence studies need to be carefully designed, the research question clearly defined and addressable with the available RWD source, variables (treatment, outcome, covariates) operationalized, and hypotheses and analyses specified before data access. Sound interpretation of results requires a deep understanding of the benefits and limitations of RWE studies, including often deficient data quality, confounding, and other potential sources of bias. Registered protocols, registered reports as a publishing model, and/or restricted access to data until protocols are in place can be encouraged by journals and enforced by data guardians and will contribute to the emergence of high-quality RWD studies. Here, we summarize guidance documents on generating RWE of treatment effectiveness or comparative effectiveness, discuss the strengths and limitations of RWD and RWE, and provide recommendations for conducting effectiveness RWE studies in the pain field.
- 3 September 2025
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (1) , 8-18
Open AccessReal-world data and evidence in pain research: an IMMPACT comprehensive review and best practice recommendations
Real-world data (RWD) can be defined as routinely collected clinical or administrative data that might be used for research purposes and to generate real-world evidence (RWE). Computerized search and data mining methods, large electronic databases, and the development of novel computational and statistical methods allow for improved access to and analysis of RWD. Although RWD afford the opportunity to generate RWE with potentially improved efficiency and generalizability over prospective clinical studies, it is important to understand and apply best practices when analysing RWD, particularly when the goal is to generate RWE of diagnostic, prognostic, or treatment effectiveness. Real-world evidence can provide evidence complementary to randomized clinical trials (RCTs), especially in scenarios where RCTs are difficult to conduct. Real-world evidence studies need to be carefully designed, the research question clearly defined and addressable with the available RWD source, variables (treatment, outcome, covariates) operationalized, and hypotheses and analyses specified before data access. Sound interpretation of results requires a deep understanding of the benefits and limitations of RWE studies, including often deficient data quality, confounding, and other potential sources of bias. Registered protocols, registered reports as a publishing model, and/or restricted access to data until protocols are in place can be encouraged by journals and enforced by data guardians and will contribute to the emergence of high-quality RWD studies. Here, we summarize guidance documents on generating RWE of treatment effectiveness or comparative effectiveness, discuss the strengths and limitations of RWD and RWE, and provide recommendations for conducting effectiveness RWE studies in the pain field.